Our findings suggest that GOLPH3L plays a critical oncogenic role in ovarian cancer progression, and highlight its potential as a therapeutic target for overcoming cisplatin resistance in ovarian cancer therapy. The gene discussed is GOLPH3L; the disease is ovarian cancer.